Berkley Renewables, Inc. · CSE:BKS
Berkley Renewables — Investor Presentation (July 2019)
18 slides from Berkley Renewables's investor presentation, July 2019
Slide 1: Energy for Today. Opportunities for Tomorrow.
Energy for Today. Opportunities for Tomorrow. July 2019
Slide 2: Diversified, Growth-Oriented Venture Company Pursuing Opportunities in Solar Energy
DIVERSIFIED, GROWTH-ORIENTED VENTURE COMPANY PURSUING OPPORTUNITIES IN SOLAR ENERGY 2
Slide 3: Exchange Listings
Exchange Listings CNSX (Canadian National Stock Exchange): Symbol BKS US OTC: Symbol BRKDF Frankfurt: Symbols WKN 871666, W80 (ISIN CA0844961080) 3
Slide 4: Overview
Overview Developing solar PV projects in Ontario, Canada through innovative flow-through investment vehicles Aggressive management team building long-term growth strategy Key investment interest: Life Sciences 4
Slide 5: Growth Strategy
Growth Strategy Through its 95% subsidiary Solar Flow-Through 2013-I Limited Partnership (Solar Flow-Through, a division of Solar Flow-Through Funds), Berkley develops and operates solar PV projects in Ontario, Canada. Ontario is North America’s second leading jurisdiction for new solar projects. So
Slide 6: Solar Energy: Ontario, Canada
Solar Energy: 6 Ontario, Canada
Slide 7: Solar Photovoltaic (PV) Power
Solar Photovoltaic (PV) Power One of the most environmentally friendly power technologies Solar modules operate silently, producing direct current (DC) electrical energy from sunlight and daylight 7
Slide 8: The Ontario FIT Program
The Ontario FIT Program Energy production revenue stream backed by government- guaranteed energy Feed-in-Tariffs (FIT) and 20-Year power purchase agreements through Independent Electricity System Operator (IESO) Ontario’s clean energy initiatives have attracted billions of dollars in new private sec
Slide 9: Solar Flow-Through in 2017/2018
Solar Flow-Through in 2017/2018 Solar Flow-Through’s 2012, 2013, 2014, 2015 and 2016 LPs together with development partners, have over 180 projects receiving FIT Contracts Awarded additional 185 FIT 5 projects = 81 kW AC in Q2 2017 2016 LP raised over $14M First set of FIT 3.1 rooftop projects compl
Slide 10: Berkley Income from Solar Flow-Through
Berkley Income from Solar Flow-Through Berkley earns 95% of the management fees earned by its Solar Flow-Through subsidiary Developing own solar projects in Ontario under FIT program Future LP’s planned in conjunction with Solar Flow-Through 10
Slide 11: Life Sciences Assets
Life Sciences Assets: 11
Slide 12: RepliCel Life Sciences Inc.
RepliCel Life Sciences Inc. Regenerative medicine company focused on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function Developed and patented hair cell replication technology that offers a potential solution for
Slide 13: RepliCel Life Sciences Inc.
RepliCel Life Sciences Inc. RepliCel completed a Collaboration and Technology Development Agreement with cosmetics giant Shiseido Recently announced a Strategic Partnership with YOFOTO (China) Health Industry Co. Ltd. YOFOTO will have an exclusive license to three RepliCel products in Greater China.
Slide 14: RCH-01 for Hair Regeneration
RCH-01 for Hair Regeneration RCH-01 treatment has the potential to become an effective, non-surgical treatment for pattern baldness and other forms of hair loss in both men and women Based on autologous* cell implantation technology that replicates a patient’s hair cells from their own healthy hair
Slide 15: RCT-01 for Chronic Tendon Injuries
RCT-01 for Chronic Tendon Injuries Initiating clinical development of a new autologous* cell therapy for the treatment of a variety of chronic tendon injuries. Based on the company’s core understanding of the unique biological function of hair follicle cells Clinical trial data, reported March 2017,
Slide 16: RCS-01 for Aging & Sun-Damaged Skin
RCS-01 for Aging & Sun-Damaged Skin Using collagen-rich fibroblasts, derived from autologous* cells, to reverse skin damage. Based on the company’s core understanding of the unique biological function of hair follicle cells Reported statistically and clinically significant positive data from interim
Slide 17: RCS-02 Dermal Injector
RCS-02 Dermal Injector Next-generation dermal injector designed to provide an improved level of control and precision for intradermal (dermis), subcutaneous (fat) or intramuscular injections Announced granting of a key U.S. patent in 2017, covering significant components of the company’s multi-needl
Slide 18: Contact
Contact Corporate Headquarters: Suite 900, 570 Granville St. Vancouver, BC V6C 3P1 (604) 682 3701 info@berkleyrenewables.com www.berkleyrenewables.com 18
Berkley Renewables — Investor Presentation (July 2019) on 6ix